NGM BIOPHARMACEUTICALS INC Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019
Cash flows from operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense
Reduction in related party contract asset due to Amended Collaboration Agreement with Merck
Depreciation
(Accretion of discount) amortization of premium on marketable securities
Noncash lease expense
Other noncash expenses
Changes in operating assets and liabilities:
Related party receivable from collaboration
Related party contract asset
Prepaid expenses and other assets
Accounts payable
Accrued and other liabilities
Operating lease liability
Deferred rent
Contract liabilities
Other noncurrent liabilities
Net cash used in operating activities
Cash flows from investing activities
Purchase of marketable securities
Proceeds from maturities of marketable securities
Purchase of property and equipment
Net cash provided by (used in) investing activities
Cash flows from financing activities
Proceeds from Open Market Agreement, net
Proceeds from exercise of stock options
Proceeds from employee stock purchase plan
Proceeds from follow on offering, net
Proceeds from initial public offering, net of issuance costs
Proceeds from private placement of common stock
Deferred offering costs paid
Net cash provided by financing activities
Net (decrease) increase in cash and cash equivalents
Cash, cash equivalents and restricted cash, at beginning of period
Cash, cash equivalents and restricted cash, at end of period
Cash and cash equivalents
Restricted cash
Supplemental disclosures of noncash investing and financing activities:
Property and equipment purchases not yet paid
Deferred offering costs accrued and not yet paid
Right of use asset acquired under operating lease on the adoption of ASC 842
Net exercise of convertible preferred stock warrant to Series A preferred stock
Vesting of common stock from early exercises
Cost of property and equipment in accounts payable and accrued liabilities

Comments